Management of the patient with oral epithelial dysplasia depends on the ability to predict malignant transformation. Histological grading of this condition fails in this regard and is also subject to inter and intra-pathologist variability. This study uses longitudinal clinical samples to explore the prognostic value of a previously validated panel of methylation biomarkers in a cohort of patients with histologically proven oral dysplasia. Methylation enrichment pyrosequencing assays were employed to provide the sensitivity of traditional methylation specific PCR (MSP) with the additional specificity advantages of a subsequent confirmatory sequencing reaction. In 57% (8/14) patients with a lesion that transformed to oral squamous cell carcinoma (OSCC), 26% (26/100) of longitudinal samples collected over ≥ 3 years demonstrated p16 methylation. Only 1% (2/184) of samples from 8% of patients (2/24) not undergoing malignant transformation within 3 years had p16 methylation. Both of these samples with p16 promoter methylation were the most recently collected and the patients remain under continuing clinical review.
p16 promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. , Janet M Risk 1 .
Introduction
Leukoplakia and erythroplakia 1 are the most common precursor lesions of oral squamous cell carcinoma (OSCC). Dysplasia is reported to be present in up to 25% of biopsies of leukoplakia whereas the majority of erythroplakia are expected to harbour dysplastic features which frequently amount to severe dysplasia or carcinoma in-situ 2 .
Optimal management of these patients depends on the ability to predict malignant transformation thus allowing for closer monitoring, risk factor reduction, surgical excision or pharmacological intervention.
The conventional management of oral epithelial dysplasia (OED) is based on histological grading into mild, moderate and severe dysplasia and carcinoma in-situ.
Sites such as floor of mouth and ventral tongue, and non-homogenous and red lesions are cited as high risk 3;4 . However, only two significant prognosticators were identified in one recent study, namely clinical appearance of lesion and size 3 . The grading of dysplasia did not correlate with the course of the lesions, a finding reported by others 5 .
Additionally, inter and intra-pathologist variability in grading of dysplasia is well described and may act as a confounding factor 6 . A further limitation in the search for predictive markers is the relatively low frequency (<1-18% 4 ) with which such premalignant lesions actually acquire invasive potential although this may be as high as 50% when severe dysplasia or carcinoma in-situ is present 2 .
Allelic imbalance and ploidy analysis have been reported to be useful in prediction of progression, although neither has translated into the clinical setting. Loss of heterozygosity (LOH) at 3p and 9p has been suggested to increase the risk of malignant progression by a factor of 3.8, whilst additional loss on chromosome arms 4q, 8p, 11q or 17p leads to a 33-fold increase in risk 7 . However a significant number of dysplastic lesions (47%) investigated by Tabor et al 8 showed no detectable LOH and four nondysplastic lesions showed extensive losses. The significance of ploidy analysis remains controversial with the recent retraction of several prominent studies by Sudbo 9;10 . Some evidence supports ploidy abnormalities in leukoplakia although the previously reported prognostic importance has not been substantiated 11 .
Few studies have investigated promoter methylation in the setting of OED.
Unfortunately, none of the previously published reports have longitudinal clinical follow up and therefore cannot correlate molecular changes with malignant progression. Some of these studies investigated OED in clinically normal mucosa at the periphery of invasive squamous cell carcinoma 12;13 although this strategy clearly introduces bias.
Variable rates of p16 methylation ranging from 28% to 75% have been reported [11] [12] [13] , while methylation of the MGMT gene has been shown to be methylated in 56% of leukoplakia 14 and in 41% of normal appearing mucosa adjacent to tumour 12 .
Investigation of promoter methylation of tumour suppressor genes in the setting of OED seems appropriate given the relatively high frequency of this epigenetic change in OSCC itself 15 and the numerous reports of methylation in premalignant lesions at other sites 16 including breast 17 , pancreas 18 , cervix, oesophagus 19 and stomach 20 . Early epigenetic changes could predispose cells to further genetic abnormalities that allow progression of the neoplastic process. For example, silencing of p16 may allow epithelial cells to escape senescence leading to genetic instability and permit accumulation of genetic mutations 17 and p16 methylation has been suggested as a valuable biomarker in the prediction of malignant change in gastric dysplasia 20 . Furthermore, the potential for demethylation and re-expression of p16 and RAR-by 5-aza-2-deoxycytidine has been shown in OED cell lines 21 .
Methods of evaluating and quantifying methylation in clinical samples continue to evolve. All previous studies of OED have utilised methylation specific PCR (MSP).
Although highly sensitive, this method lacks internal control for adequacy of bisulphite treatment and is prone to false positives, which can occur relatively frequently, particularly when a high number of PCR cycles are used 22 . Pyrosequencing offers the advantage of relatively high throughput with confirmation of adequacy of bisulphite treatment and is semi-quantitative. Methylation enrichment pyrosequencing (MEP) is a relatively recently described modification of these two techniques that utilises methylation specific primers but is followed by a confirmatory pyrosequencing step that allows elimination of false positives 22 . This is particularly appropriate in the analysis of samples where target DNA concentrations may be low, such as mucosal scrapes and saliva. These surrogate samples have been shown to be useful in the investigation of oral squamous cell carcinoma (OSCC) with studies demonstrating good agreement of LOH patterns between OSCC and DNA extracted from saliva and lesion brushings 23 .
Surrogate samples are non-invasive and seem more acceptable to the patient as a means of OED surveillance than continual biopsy.
In order to exploit the preponderance of molecular data generated in cancer research to develop clinically valuable strategies in OED, two challenges are apparent.
Firstly to identify biomarkers that predict those lesions at high risk for progression with high sensitivity and specificity, and second, to determine if the underlying molecular aberrations are amenable to pharmacological intervention.
The aim of this study is to explore the prognostic value of a panel of methylation biomarkers previously validated in OSCC 15 in a cohort of patients with OED. This study utilises longitudinal tissue collection from a patient cohort with prolonged clinical followup. We describe the utility of non-invasive oral scrapes as a surrogate for repeated invasive biopsies, and our assays make use of MEP in order to improve the specificity and sensitivity of the methylation assays.
Materials and methods

Patients
Patients with biopsy proven OED were prospectively enrolled in the study subject 
DNA extraction
For both scrapes and tissue samples, DNA was extracted using a phenolchloroform based extraction procedure which gives superior yield from small samples 24 .
Bisulphite treatment of each sample was undertaken using the EZ DNA methylation kit (Zymo Research). A quality check of converted DNA was performed using pyrosequencing methylation assay (PMA) primers 15 specific for bisulphite treated DNA, which confirmed the DNA content prior to analysis and assessed the efficiency of bisulphite conversion using an internal control (a C residue not followed by a G residue in the sequence being examined, which will not be subject to methylation and therefore should be completely converted to Uracil). Any samples showing less than 100% conversion were rejected as these are likely to produce false +ves in any methylation dependent assay.
Methylation analysis
Methylation enrichment pyrosequencing (MEP) was employed as previously described 22 . . Pyrosequencing was carried out using the PSQ96MA System (Biotage) according to manufacturer"s protocol, as previously described 15 .
Statistical analysis
Differences in methylation frequency between NT and T groups were tested using Fishers Exact test. Tests involving samples were not undertaken because interdependence of samples from the same patient was assumed. Differences in the number of methylated genes between NT & T patient groups were tested using the Mann-Whitney Test.
Results
Clinical
Of the 24 patients in the NT group, 13 (54%) had mild, 5 (21%) moderate and 6 (25%) had severe OED on the initial biopsy. Of the 14 patients in the T group 6 (43%) had mild, 3 (21%) moderate and 5 (36%) severe OED, although several patients underwent subsequent biopsies that showed a progression to a higher grade. The differences were not significant. There was also no significant difference in the distribution of affected sub-sites between NT and T groups (data not shown). Smoking history was obtained in 22 of the 24 NT patients. Only 2 had never smoked, most having sustained the habit over a prolonged (>20 year) period. Four of the 14 T patients denied ever smoking, 6 were current long term smokers and there were 3 ex-smokers.
Gene promoter methylation analysis
In total, 293 gel positives were obtained from all investigated genes, of which 65%
were eliminated either as unmethylated or as non-target PCR products (i.e. the pyrosequencing reaction failed).
p16
Methylation of the p16 promoter predicted for malignant transformation, being present in 26% (26/100) of samples from T patients compared with 1% (2/184) of samples from the NT group (Table 2 ). Overall, 57% of patients from the T group were positive in at least one scrape compared with only 8% of patients from the NT group (Fishers Exact P=0.002). Furthermore, this p16 promoter methylation was retained in subsequent samples in 4/5 patients where the first sample testing positive was not the most recently collected. Almost twice as many of the positive samples in the T group were from lesions than from normal tissue (Table 3) . Notably, only 2 samples showed p16 promoter methylation amongst the NT group and these samples were the most recently collected from those patients. Transforming patients who demonstrated methylation of the p16 promoter (n=8; Table 2 ) displayed variable time intervals between their first presentation of p16 promoter methylation and the development of OSCC (range 0-70 months; median 18 months) which did not appear to correlate with pathological staging.
Cyclin A1 (CCNA1)
Methylation at this gene promoter was similar between T (50%) and NT (58%) patient cohorts (Table 2) , however, a tendency for methylation in the T samples was observed (12% vs. 22%). Within both groups, the majority of positive samples were derived from clinically apparent lesions (Table 3) .
Cytoglobin (CYGB)
Methylation at CYGB was frequent in both cohorts, seen in 46% and 57% of patients in the NT and T groups respectively (Table 2) . Methylation was seen in 10% of NT samples compared with 25% of samples from the T group. Methylation was observed more consistently in longitudinal samples from the T group, whereas a more sporadic distribution of positive results were seen in the NT group, leading to the frequency of positive samples from normal and lesional tissue shown in Table 3 .
MGMT
MGMT showed the lowest level of methylation with only 3% and 4% of NT and T samples respectively being positive, corresponding to 21% and 29% of patients. The positive samples were usually solitary findings amongst multiple negative samples thus explaining the discrepancy between the percentages of positive samples and patients.
Methylation at multiple gene promoters
The number of genes showing promoter methylation in each patient was compared between the two groups ( Table 4) 
Methylation in oral scrapes vs corresponding biopsy tissue
Where both incisional biopsy and corresponding scrape material was available 
Discussion
This study demonstrates that methylation of p16 in oral epithelial dysplasia (OED)
is potentially a specific predictive marker of malignant transformation. However, it has limited sensitivity as only 57% of the transforming patients showed this change. In our cohort, histological grading of dysplasia neither correlated with development of invasive carcinoma, in keeping with previous reports 
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. This was highlighted in our study by the proportion of samples in which "gel positive" products were subsequently rejected following pyrosequencing. These failures include priming from unmethylated alleles thus generating unmethylated products and mispriming, which is known to be a problem with low concentrations of target DNA and high numbers of PCR cycles. MEP offers several advantages in clinical samples of this type. A relatively large sample set can be processed at moderate cost since only "gel positive" samples require the confirmatory pyrosequencing step. Validation by pyrosequencing allows the exclusion of all false positive results and also checks for adequacy of bisulphite conversion. Furthermore, the quantity of DNA obtained from a mucosal scrape may be small and will almost certainly include contaminating oral tissue and salivary DNA. In these situations, MEP is an ideal technique due to its high sensitivity and ability to detect methylation in clinical samples with low concentrations of methylated DNA.
p16 promoter methylation offers promise as a predictive biomarker differentiating between stable and transforming OED. It is noteworthy that in the two NT patients demonstrating p16 methylation, the change was detected only in the most recent sample. Attempts to compare our data with other published studies are difficult due to differences in methods and lack of clinical follow-up in the literature. Kresty et al 25 reported methylation of p16 in 58% patients with severe dysplasia while Lopez noted relatively high rates of methylation at p16 (44%) and MGMT (56%) in DNA extracted from mouthrinse 14 , and for p16 this was slightly increased in patients with persistent leukoplakia and a history of OSCC. p16 was shown to be methylated in 75% of OED patients enrolled in a chemopreventive trial 13 , with 38% demonstrating reversal during the course of the study. However, correlation of methylation with outcome was not specifically stated and an apparent association between methylation and increasing severity of dysplasia was noted, in contrast to our findings., More recently, Kato and colleagues 12 determined methylation status of p16 and MGMT in OSCC, tumour adjacent mucosa, and mucosa from healthy volunteers. No methylation was found in the latter group, but it was present at high rates in OSCC (51% and 56% for p16 and MGMT respectively). Clinically normal oral mucosa adjacent to tumour showed an intermediate frequency of methylation (27% and 40%). In our current study 26% of all patients demonstrated p16 methylation, clearly at the lower end of the previously reported rates (27-75%) . One explanation may be false positive MSP results in previous studies. The prevalence of p16 methylation in our previous (unrelated) cohort of OSCC patients (27%) 15 was lower than that of our transforming cohort of OED (57%). This might suggest that p16 methylation may be more common in OED-derived OSCC, or perhaps represents a transient stage in malignant transformation. However we are cautious in this conclusion because in our previous study the criteria for p16 methylation in tumour tissue were significantly more stringent than in this study (>5% methylation using a quantitative assay [PMA] compared with a qualitative [yes/no] assay [MEP]).
To our knowledge, this is the first study that investigates CCNA1 and CYGB in OED. Although methylation at the promoters of these genes was prevalent in OED, this did not predict malignant transformation. Our data for MGMT conflicts with that previously published in OED with very few samples showing methylation (3% and 4%).
In a cohort of OSCC in which the same CpG islands were analysed In this study, the finding of methylation rates between 23-50% in clinically normal mucosa from OED patients (Table 3 ) is in keeping with concept of field change 26 and implies that molecular aberrations extend far beyond the limits of histological and clinical detection. As previously reported, the histological grade of dysplasia did not predict malignant transformation 3 but notably there were a higher proportion of non-smokers amongst the T group. This is consistent with the findings that although smoking is a risk factor for development of OED, the habit appears not to be associated with additional cancer risk 27 . This is also corroborated by our previous work, which demonstrated methylation at the p16 gene in only 4% of clinically/histologically normal mucosa from 70 patients, 57% of whom were heavy smokers 15 .
Limitations of the present study include the small number of genes selected for study and the relatively small size of the cohort. The 4 genes chosen for analysis were selected from 10 reported in the literature as most frequently methylated in OED and OSCC 28 , and were subjected to validation as tumour specific by pyrosequencing 15 . In order to address the lack of sensitivity of a single methylation marker such as p16 in Table 1 Gene PCR and pyrosequencing primers and PCR annealing temperature.
CCNA1: cyclin A1; CYGB: cytoglobin; MGMT: 6-O-methylguanine DNA methyltransferase.
Biotin: the indicated primers were 5" biotin labelled to enable preparation of the appropriate single stranded DNA for subsequent pyrosequencing reactions. Table 2 Frequency of gene promoter methylation in the non-transforming (NT) and transforming Distribution of gene promoter methylation in normal (N) and dysplastic (D) lesions in the non-transforming (NT) and transforming (T) cohorts
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